Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, reduced itch and hives in patients with chronic spontaneous urticaria and showed a favorable safety profile at week 12 in two trials.